Back to Top
  • COVID-19 Update: Remote Operations in Effect

     

    Until further notice, CSU Pueblo is serving our students and the public in a remote model.

Keynote Speakers

Dr. Roger Pertwee

allyn-howlett.jpg

Roger Pertwee, Ph.D. will deliver the Mechoulam Lecture at the Institute of Cannabis Research – 2020 Conference. Dr. Pertwee was personally recommended by Dr. Raphael Mechoulam for this honor.

Roger Pertwee has three degrees from the University of Oxford: MA (in biochemistry), D.Phil. (in pharmacology) and D.Sc. (in physiological sciences). He is an Emeritus Professor at the University of Aberdeen, where he is still actively engaged in scientific cannabinoid research. He is also an invited scientific advisor on cannabinoid pharmacology/therapeutics to the Beckley Foundation, and has formal links with GW Pharmaceuticals.

In addition, he is co-chairman of the International Union of Basic and Clinical Pharmacology (IUPHAR) Subcommittee on Cannabinoid Receptors, has served twice as President of the International Cannabinoid Research Society (ICRS; 1997-1998 and 2007-2008), and once as chairman of the International Association for Cannabinoid Medicines (IACM; 2005-2007), and is currently serving as International Secretary of the ICRS and as a member of the IACM Board of Directors.

He received the 2002 Mechoulam Award “for his outstanding contributions to cannabinoid research”, the British Pharmacological Society (BPS) 2011 Welcome Gold Medal “for outstanding contributions to pharmacology, based mainly on research achievements”, the 2013 IACM Special Award “for his major contributions to the re-introduction of cannabis as a medicine”, the 2018 Lifetime Achievement Award from the ICRS “for outstanding contributions to cannabinoid research and to the ICRS”, and Highly Cited Researcher Awards from Thomson Reuters in 2014 “in recognition of ranking among the top 1% of researchers for most cited documents in their specific field”, and from Clarivate Analytics in 2018 “in recognition of exceptional research performance demonstrated by production of multiple highly cited papers, those that rank in the top 1% by citations for field and year in Pharmacology and Toxicology”.

He is also an Honorary Fellow of the BPS. His research has focused mainly on the pharmacology and therapeutic potential of cannabinoids. This cannabinoid research began in 1968 at Oxford University and continued when he moved to Aberdeen University in 1974. His achievements include (1) the demonstration that cannabidiol is a highly effective inhibitor of certain hepatic microsomal enzymes, (2) the development of assays such as the in vivo “ring immobility test”, and the in vitro mouse vas deferens assay for CB1 receptor agonists, (3) discovering the basis of the hypothermic effect of delta-9-tetrahydrocannabinol in mice, and (4) the joint discovery both of delta-9-tetrahydrocannabivarin in cannabis, and of endocannabinoids (anandamide and 2-arachidonoylglycerol), the discovery of a CB1 receptor allosteric site, and significant contributions to the pharmacological characterization both of phytocannabinoids (e.g. delta-9 tetrahydrocannabivarin, cannabidiol, cannabidiolic acid and cannabigerol) and of notable synthetic cannabinoids (e.g. methanandamide, ACEA, ACPA, AM281, AM630, HU-308, HU-580, O-1057 and Org27569).   

Aerial shot of campus fountain

Campus Safety: Coronavirus (COVID-19)

We have a number of individuals working on a plan to ensure that we are prepared to take care of our students and employees in the event our campus is directly impacted by the coronavirus.

Back to Top